Skip to content
God Of Sound – Lifestyle
Author:
Aquestive Therapeutics, Inc.
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
November 9, 2026
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
November 5, 2026
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 3, 2026
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
October 27, 2026
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
October 15, 2026
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
September 29, 2026
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
September 17, 2026
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
September 1, 2026
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
August 10, 2026
1
2
Next Page
→